EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer

Khushboo A Gandhi, Aditi Shirsat, Sharat Kumar Hj, Ashish Chavan, Parnika Dicholkar, Saniya Shah, Nandini Menon, Vanita Noronha, Amit Joshi, Kumar Prabhash, Vijay Patil, Vikram Gota

Cancer Chemotherapy and Pharmacology · 2024-11 · 94 (5) · 659-668

DOI: 10.1007/s00280-024-04697-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 26.07.2024. Verfasst von Khushboo A Gandhi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC) Sector- 22,…. Hauptthemen laut MEDLINE: Nivolumab, Neoplasms, Dose-Response Relationship, Drug, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) - Khargar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Nivolumab is approved at various doses, including 3 mg/kg, 240 mg and 480 mg flat doses at various dosing intervals. The concept of low-dose immunotherapy is gaining traction in recent years. However, there is a need to better understand the pharmacokinetics and clinical outcomes at lower doses.

Methods

Patients were either administered 40 mg flat dose or 3 mg/kg Q2W/Q3W, depending on affordability as per prevailing hospital practice. All patients were hospitalized on day 1 and pharmacokinetic samples were collected at 0, 0.5, 1.0, 6.0, 24.0, 72.0 h and day 14 following administration of the first dose of nivolumab. Plasma nivolumab levels were measured by ELISA. Patients were followed up for response and toxicity.

Results

Twenty five patients were included in the study. Fourteen received nivolumab at conventional dose (3 mg/kg), while 11 patients received low-dose (40 mg flat). The geometric means of dose normalized C max and AUC 0-t were comparable between those who received conventional dose and low-dose of nivolumab (0.28 versus 0.23 µg/mL/mg and 0.0014 versus 0.0011 d/mL respectively). Nineteen patients were evaluable for response. ORR among patients who received conventional dose was 5/11 (45.5%) whereas it was 4/9 (44.4%) in the low-dose cohort. All 14 (100%) patients in conventional dosing group and 7/11 patients (63.64%) in low-dose group had treatment emergent adverse events. Grade ≥ 3 toxicities were observed in 4/14 patients in conventional dose group and none in low-dose group.

Conclusion

Low-dose nivolumab leads to lower exposure in patients as compared with conventional dose, but low-dose was better tolerated, while response rates were comparable to conventional dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabNeoplasmsDose-Response Relationship, DrugAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedAgedAdultTreatment OutcomeArea Under CurveImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Conventional doseLow-doseNivolumabPharmacokineticsResponseToxicity

Substanzen

NivolumabAntineoplastic Agents, ImmunologicalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC) Sector- 22, Kharghar, Navi Mumbai, 410210, India.
  • Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, 400012, India.
  • Homi bhabha National Institute, Mumbai, 400094, India.
  • Department of Medical Oncology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC), Kharghar, Navi Mumbai, 410210, India.
  • Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC) Sector- 22, Kharghar, Navi Mumbai, 410210, India. vgota76@gmail.com.
  • Homi bhabha National Institute, Mumbai, 400094, India. vgota76@gmail.com.

Förderung

  • Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) - Khargar

Zitieren

APA

Gandhi, K. A., Shirsat, A., Hj, S. K., Chavan, A., Dicholkar, P., Shah, S., Menon, N., Noronha, V., Joshi, A., Prabhash, K., Patil, V., & Gota, V. (2024). Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 94(5), 659-668. https://doi.org/10.1007/s00280-024-04697-x

Vancouver

Gandhi KA, Shirsat A, Hj SK, Chavan A, Dicholkar P, Shah S, et al. Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 2024;94(5):659-668. doi:10.1007/s00280-024-04697-x

BibTeX
@article{Gandhi2024,
  author = {Gandhi, Khushboo A and Shirsat, Aditi and Hj, Sharat Kumar and Chavan, Ashish and Dicholkar, Parnika and Shah, Saniya and Menon, Nandini and Noronha, Vanita and Joshi, Amit and Prabhash, Kumar and Patil, Vijay and Gota, Vikram},
  title = {Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  volume = {94},
  number = {5},
  pages = {659--668},
  doi = {10.1007/s00280-024-04697-x}
}
Kostenlos starten →